Treatment for peritoneal metastasis of colorectal cancer
10.3760/cma.j.issn.0529-5815.2018.08.003
- VernacularTitle: 结直肠癌腹膜转移治疗的争议与思考
- Author:
Lei WANG
1
;
Jian CAI
;
Qiyuan QIN
Author Information
1. Department of Colorectal Surgery, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Peritoneal neoplasms;
Treatment
- From:
Chinese Journal of Surgery
2018;56(8):569-572
- CountryChina
- Language:Chinese
-
Abstract:
Peritoneal metastasis is the second leading cause of death of colorectal cancer patients. Cytoreductive surgery (CRS) combined with hyperthermia intraperitoneal chemotherapy (HIPEC) is the primary method to treat peritoneal metastasis of colorectal cancer, though there remain some controversies. We reviewed current studies of colorectal peritoneal carcinomatosis (PC) and CRS+ HIPEC, and discussed some issues with regard to the scoring system for peritoneal metastasis, selection criteria for CRS+ HIPEC treatment, and the new drug application for colorectal PC. Peritoneal carcinomatosis index (PCI) is the most useful scoring system for peritoneal metastasis and CRS+ HIPEC is the primary treatment for colorectal PC. Patients with PCI<20 should receive thorough assessment on the feasibility of R0 or R1 resection and CRS+ HIPEC treatment. For patients with unresectable PC at the initial stage, active drug therapy should be adopted to achieve tumor regression, so that some of them would have the opportunity to receive CRS+ HIPEC treatment.
